Previous 10 | Next 10 |
Positive findings in third line and greater metastatic pancreatic cancer patients (N=83) with doubled median overall survival (OS) versus historical OS Median overall survival of 5.8 months and 61% of patients (51/83) exhibited disease control All treatments in an outpatient setting of co...
Summary Lead drug candidate improves on listed standard treatment. Marketing authorization is within reach in 5 months, but the FDA might balk even with a pre-approved trial design. The company has money to at least last that long, but approval isn't a sure thing. Immunity...
Summary ImmunityBio, Inc. presented strong data from its lead asset in multiple indications. Lead indication has a May 23 PDUFA. I am not sure I understand how this company operates, in terms of money, I mean. ImmunityBio, Inc. ( IBRX ) is another Patrick Soon-Shiong c...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . For further details see: Wall Street Breakfast: Shifting Gears
Immunotherapy company ImmunityBio ( NASDAQ: IBRX ) said it is launching ~$50M registered direct offering. The issuance of common stock as well as warrants for the purchase of additional shares will be made to a single institutional investor. ImmunityBio has agreed t...
Financing transactions include approximately $50 million of equity financing from a single institutional investor, $50 million of debt financing from Nant Capital, LLC, and conversion of approximately $56.6 million of debt held by NantWorks LLC into ImmunityBio equity. Additional equity finan...
ImmunityBio, Inc. ( NASDAQ: IBRX ), a clinical-stage immunotherapy company, announced today that the company will be participating in the 34 th Annual Piper Sandler Healthcare Conference, which is taking place in New York City, November 29 - December 1, 2022. Details of the ...
Primary endpoint met in high-risk carcinoma in situ (CIS) cohort with 71% complete response rate (CR) with a median duration of response of 26.6 months, a 53% CR rate at 24 months and a safety profile comparable to BCG alone This novel IL-15 superagonist N-803 – referred to...
ImmunityBio, Inc. ( NASDAQ: IBRX ), a clinical-stage immunotherapy company, announced today that the company will be presenting at the Jefferies London Healthcare Conference, which is taking place in London from November 15-17, 2022. Details of the presentation can be found ...
Summary ImmunityBio operates an effective development program for infectious disease, and more interestingly, oncology therapies. Its duly accepted BLA will be in the spotlight as its PDUFA date rolls around. The company's attraction as an investment is uncertain and should on...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 01:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into ImmunityBio, Inc. (NasdaqGS: IBRX). On May 11, 2023, the Company disclosed that it had receiv...